Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Pharmaceutical and Biomedical Analysis|June 9, 2018
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patientsRafael Reis, Laurence Labat, Marie Allard, et al.
Cancers|May 14, 2022
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie HospitalsClelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, et al.
British Journal of Clinical Pharmacology|February 25, 2024
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approachAlexandre Acramel, Sandy Blondeel-Gomes, Mathilde Dupré, et al.
Oncotarget|September 3, 2016
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinibGaёlle Noé, Audrey Bellesoeur, Audrey Thomas-Schoemann, et al.
Cancers|June 5, 2019
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with NivolumabGaëlle Noé, Audrey Bellesoeur, Lisa Golmard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2019
The impact of body composition parameters on severe toxicity of nivolumabLaure Hirsch, Audrey Bellesoeur, Pascaline Boudou-Rouquette, et al.
Therapeutic Advances in Medical Oncology|April 26, 2024
Improving olaparib exposure to optimize adverse effects managementMarylise Sterlé, Alicja Puszkiel, Chloé Burlot, et al.
Fundamental & Clinical Pharmacology|October 22, 2017
Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French studyLuc Cabel, Benoit Blanchet, Audrey Thomas-Schoemann, et al.
Scientific Reports|November 7, 2025
Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie HospitalsAlexandre De Moura, Orane Gleizes, Luc Cabel, et al.
Bulletin Du Cancer|December 20, 2025
[A 2025 inventory in oncology news]Stéphane Vignot, Audrey Bellesoeur, Delphine Borchiellini, et al.
Pageof 3